Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)

Gepotidacin, a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development for treatment of uncomplicated urinary tract infection (uUTI). This phase 2a study in female participants with uUTI evaluated the pharmacokinetics (primary objective), safety, and exploratory efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Overcash, J. Scott, Tiffany, Courtney A., Scangarella-Oman, Nicole E., Perry, Caroline R., Tao, Yu, Hossain, Mohammad, Barth, Aline, Dumont, Etienne F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318048/
https://www.ncbi.nlm.nih.gov/pubmed/32284384
http://dx.doi.org/10.1128/AAC.00199-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318048/
https://www.ncbi.nlm.nih.gov/pubmed/32284384
http://dx.doi.org/10.1128/AAC.00199-20

Ejemplares similares